Bio X Cell

bxcell.com

Bio X Cell is a biotechnology company that manufactures high quality, bulk quantity (milligram to gram) monoclonal antibodies for biomedical research.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

news image

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More

K-COSMECEUTICAL COMPANY DERMAFIRM USA, INC. OFFICIALLY ANNOUNCED ITS U.S. EXPANSION

PR Newswire | July 22, 2020

news image

Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea's Dermafirm Inc., is officially announcing its U.S. expansion. Plans are to formally introduce its U.S. leadership team on July 28th, at a private, virtual event. During the event, the company will kick off a movement with a mission to embrace scientific innovation, educate consumers on clean, natural and healthy DIY skincare options and ultimately empower users to perform these skincare regimens safely at hom...

Read More

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

news image

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More

Industry Outlook

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

news image

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More
news image

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More
news image

K-COSMECEUTICAL COMPANY DERMAFIRM USA, INC. OFFICIALLY ANNOUNCED ITS U.S. EXPANSION

PR Newswire | July 22, 2020

Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea's Dermafirm Inc., is officially announcing its U.S. expansion. Plans are to formally introduce its U.S. leadership team on July 28th, at a private, virtual event. During the event, the company will kick off a movement with a mission to embrace scientific innovation, educate consumers on clean, natural and healthy DIY skincare options and ultimately empower users to perform these skincare regimens safely at hom...

Read More
news image

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More
news image

Industry Outlook

TANTU AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ENGINEER A LIVING BIOTHERAPEUTIC FOR GASTROINTESTINAL HEALING

Ginkgo Bioworks | September 07, 2021

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Ta...

Read More